Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akashi-Tanaka

Showing results (101-110 of 122) with videos related to

Pageof 13
Sort By:
Acta Medica Okayama|June 28, 2013
p53 expression in pretreatment specimen predicts response to neoadjuvant chemotherapy including anthracycline and taxane in patients with primary breast cancerTadahiko Shien, Takayuki Kinoshita, Kunihiko Seki, et al.
Breast Cancer (Tokyo, Japan)|August 24, 2019
Current conditions and issues of physicians and working conditions at institutions accredited by the Japanese Breast Cancer SocietyKazumi Kawase, Hiroko Yamashita, Hirotaka Iwase, et al.
The Breast Journal|September 22, 2005
Diagnosis of complete response to neoadjuvant chemotherapy using diagnostic imaging in primary breast cancer patientsTakashi Kanazawa, Sadako Akashi-Tanaka, Eriko Iwamoto, et al.
Genes to Cells : Devoted to Molecular & Cellular Mechanisms|September 10, 2010
Up-regulation of PSF1 promotes the growth of breast cancer cellsIzumi Nakahara, Mamiko Miyamoto, Tatsuhiro Shibata, et al.
Journal of Clinical Pathology|November 29, 2005
Frequent overexpression of epidermal growth factor receptor (EGFR) in mammary high grade ductal carcinomas with myoepithelial differentiationT Shien, T Tashiro, M Omatsu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 2, 2010
Grading system for lymph vessel tumor emboli: significant outcome predictor for patients with invasive ductal carcinoma of the breast who received neoadjuvant therapyTakahiro Hasebe, Nobuko Tamura, Motoki Iwasaki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2010
FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancerK Tamura, C Shimizu, T Hojo, et al.
World Journal of Surgery|October 28, 2008
Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancerTadahiko Shien, Sadako Akashi-Tanaka, Kunihisa Miyakawa, et al.
Breast (Edinburgh, Scotland)|May 5, 2009
21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patientsSadako Akashi-Tanaka, Chikako Shimizu, Masashi Ando, et al.
Pathology International|April 18, 2015
The expression and clinical significance of ribophorin II (RPN2) in human breast cancerMakiko Ono, Hitoshi Tsuda, Takayuki Kobayashi, et al.
Pageof 13

Showing results (101-110 of 122) with videos related to

Sort By:
Pageof 13
Acta Medica Okayama|June 28, 2013
p53 expression in pretreatment specimen predicts response to neoadjuvant chemotherapy including anthracycline and taxane in patients with primary breast cancerTadahiko Shien, Takayuki Kinoshita, Kunihiko Seki, et al.
Breast Cancer (Tokyo, Japan)|August 24, 2019
Current conditions and issues of physicians and working conditions at institutions accredited by the Japanese Breast Cancer SocietyKazumi Kawase, Hiroko Yamashita, Hirotaka Iwase, et al.
The Breast Journal|September 22, 2005
Diagnosis of complete response to neoadjuvant chemotherapy using diagnostic imaging in primary breast cancer patientsTakashi Kanazawa, Sadako Akashi-Tanaka, Eriko Iwamoto, et al.
Genes to Cells : Devoted to Molecular & Cellular Mechanisms|September 10, 2010
Up-regulation of PSF1 promotes the growth of breast cancer cellsIzumi Nakahara, Mamiko Miyamoto, Tatsuhiro Shibata, et al.
Journal of Clinical Pathology|November 29, 2005
Frequent overexpression of epidermal growth factor receptor (EGFR) in mammary high grade ductal carcinomas with myoepithelial differentiationT Shien, T Tashiro, M Omatsu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 2, 2010
Grading system for lymph vessel tumor emboli: significant outcome predictor for patients with invasive ductal carcinoma of the breast who received neoadjuvant therapyTakahiro Hasebe, Nobuko Tamura, Motoki Iwasaki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2010
FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancerK Tamura, C Shimizu, T Hojo, et al.
World Journal of Surgery|October 28, 2008
Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancerTadahiko Shien, Sadako Akashi-Tanaka, Kunihisa Miyakawa, et al.
Breast (Edinburgh, Scotland)|May 5, 2009
21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patientsSadako Akashi-Tanaka, Chikako Shimizu, Masashi Ando, et al.
Pathology International|April 18, 2015
The expression and clinical significance of ribophorin II (RPN2) in human breast cancerMakiko Ono, Hitoshi Tsuda, Takayuki Kobayashi, et al.
Pageof 13